Across TCGA pan-cancer cohorts, NAP1L4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAP1L4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher NAP1L4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAP1L4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

COAD, CCRCC, and PDAC are the cancer types where NAP1L4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	III,IV	0.810	1.000	.007	60	view →
CCRCC	DFS	Quartile	II,III,IV	0.887	0.198	.024	11	view →
PDAC	DFS	Quartile	IV	0.224	0.515	.038	3	view →
LSCC	OS	Median	II,III,IV	1.000	0.908	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NAP1L4 tumor-vs-normal RNA expression · all NAP1L4 data types